Summit Therapeutics (SUMM) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock SUMM Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Summit Therapeutics director Zanganeh buys shares worth $5.9mSeptember 12 at 10:35 AM | investing.comDuggan buys Summit Therapeutics (SMMT) shares worth $5.9mSeptember 12 at 10:35 AM | investing.comGuggenheim Initiates Summit Therapeutics (SMMT) With a Buy RatingSeptember 10, 2025 | msn.comSummit shares tumble on mixed data for lung cancer drugSeptember 8, 2025 | reuters.comSummit Therapeutics Shares Plunge After Lung Cancer Drug Data DisappointsSeptember 8, 2025 | msn.comSummit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping PunchSeptember 8, 2025 | msn.comSummit Therapeutics: Dethroning Merck Was Never Going To Be StraightforwardSeptember 8, 2025 | seekingalpha.comSummit Therapeutics stock sinks after lung cancer drug data disappointsSeptember 8, 2025 | za.investing.comSummit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data DifferencesSeptember 8, 2025 | finance.yahoo.comSummit Plunges After Lung Cancer Data Disappoints Wall StreetSeptember 8, 2025 | msn.comRetail Traders Flock To Summit Therapeutics After New Cancer Drug Data Shows Survival GainsSeptember 7, 2025 | msn.comSummit Therapeutics Gets A $40 Price Target As Guggenheim Says It Likes Stock At $24, Like It Did At $3September 4, 2025 | msn.comSummit Therapeutics initiated with a Buy at GuggenheimSeptember 4, 2025 | msn.comSummit Therapeutics falls -9.4%August 28, 2025 | msn.comSummit Draws Frenzied Retail Chatter After Akeso Drug Shows Survival Benefit In Lung Cancer; Retail Sees More UpsideAugust 26, 2025 | msn.comPiper Sandler Initiates Coverage of Summit Therapeutics (SMMT) with Neutral RecommendationAugust 20, 2025 | msn.comSummit Therapeutics put volume heavy and directionally bearishAugust 19, 2025 | msn.comSummit Therapeutics initiated with a Neutral at Piper SandlerAugust 19, 2025 | msn.comSummit Therapeutics Advances as Trial Outcomes and New Collaboration Drive OptimismAugust 19, 2025 | msn.comSummit Therapeutics falls -12.5%August 13, 2025 | msn.comSummit Therapeutics price target raised to $33 from $30 at Clear StreetAugust 13, 2025 | msn.comRevolution Medicines outlines $1.03B–$1.09B net loss guidance for 2025 amid expanded global RAS portfolio strategyAugust 8, 2025 | msn.comSummit Therapeutics: Here Are (Some Of) The Reasons The Buy Thesis Is FlawedAugust 6, 2025 | seekingalpha.comSummit Therapeutics Insiders Added US$78.0m Of Stock To Their HoldingsAugust 2, 2025 | finance.yahoo.comSummit Therapeutics (SMMT) Climbs 16% Ahead of Q2 EarningsJuly 17, 2025 | finance.yahoo.comH.C. Wainwright Keeps Their Buy Rating on Summit Therapeutics (SMMT)July 16, 2025 | theglobeandmail.comMerakris Therapeutics Selected as Finalist for 2025 Advanced Would Care Summit Innovation ShowcaseJuly 15, 2025 | tmcnet.comSummit Therapeutics (SMMT) Jumps 7.6% on Reports of $15-Billion AstraZeneca DealJuly 10, 2025 | msn.comSummit, AstraZeneca (AZN) in Advanced Talks Over $15 billion Oncology Licensing DealJuly 9, 2025 | msn.comSummit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks RemainJuly 4, 2025 | seekingalpha.comUBS Initiates Coverage of Summit Therapeutics (SMMT) with Buy RecommendationJuly 2, 2025 | msn.comSummit Therapeutics Inc. Common Stock (SMMT) - NasdaqJuly 2, 2025 | nasdaq.comLineage Cell Therapeutics unveils promising Phase I/IIa OpRegen results at CTS 2025July 2, 2025 | finance.yahoo.comSummit Therapeutics (SMMT) Rated Buy on Ivonescimab’s Cancer-Fighting PotentialJuly 2, 2025 | msn.comRevolution Medicines, Summit Therapeutics Partner to Evaluate Combination of Treatments in Certain CancersJune 30, 2025 | marketwatch.com2 Stocks Too Cheap to Ignore at These PricesJune 26, 2025 | msn.comSMMT Summit Therapeutics Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comH.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 TargetJune 26, 2025 | msn.comExplaining Summit's Fall Despite Positive Data In EGFR-Positive Lung CancerJune 4, 2025 | seekingalpha.comIs SMMT Stock A Buy After Its Recent Plunge?June 2, 2025 | forbes.comSummit gains as late-stage trial for lung cancer therapy hits main goalMay 30, 2025 | msn.comSummit Therapeutics: Critical NSCLC Study Readout Jeopardizes Ivonesimab ApprovalMay 30, 2025 | seekingalpha.comPfizer's Mega Deal Highlights China's Rising Role In Global PharmaMay 29, 2025 | benzinga.comSummit Therapeutics (NasdaqGM:SMMT) Reports US$63M Net Loss For Q1 2025May 23, 2025 | finance.yahoo.comBioNTech says bispecific antibody BNT324 is competitive against Summit's ivonescimabMay 15, 2025 | msn.comSummit Therapeutics stock rating upgraded to Buy at TD CowenMay 9, 2025 | uk.investing.comWhy Summit Therapeutics Inc. (SMMT) Soared Last WeekMay 4, 2025 | msn.comSummit Therapeutics Inc. (SMMT) Q1 2025 Earnings Call TranscriptMay 3, 2025 | seekingalpha.comEarnings call transcript: Summit Therapeutics beats Q1 2025 EPS forecastsMay 3, 2025 | uk.investing.comSummit Therapeutics outlines ivonescimab progress with key Phase III data expected mid-2025May 2, 2025 | msn.com Get Summit Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SUMM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SUMM Media Mentions By Week SUMM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SUMM News Sentiment▼-0.180.94▲Average Medical News Sentiment SUMM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SUMM Articles This Week▼72▲SUMM Articles Average Week Get the Latest News and Ratings for SUMM and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Summit Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies AstraZeneca News Today GSK News Today Haleon News Today Smith & Nephew News Today Ondine Biomedical News Today ConvaTec Group News Today Hikma Pharmaceuticals News Today HUTCHMED News Today Indivior News Today Genus News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:SUMM) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Summit Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SUMM Stock Alerts